China’s NMPA Unveils Three-Year Smart Supervision Plan for Blood Product Industry
China’s National Medical Products Administration (NMPA) has unveiled the “Three-Year Action Plan for Smart Supervision...
Recorna and Starna Therapeutics Join Forces to Advance RNA Gene Editing in Lung Diseases
Recorna (Guangzhou) Biotechnology Co., Ltd, a pioneering RNA editing therapy startup based in China, has...
Novartis’s Tabrecta Earns NMPA Nod for MET-Positive Advanced NSCLC in China
Swiss pharmaceutical titan Novartis has secured marketing approval from China’s National Medical Products Administration (NMPA)...
Biosion’s Bosakitug Shows Positive Results in Atopic Dermatitis Phase II POC Study
Biosion, a clinical-stage biotechnology company with operations in Delaware, U.S., and China, has announced key...
Ascletis Pharma’s ASC41 Shows Promise in Phase II Study for Metabolic Dysfunction-Associated Steatohepatitis
Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced positive interim...
China Medical System Secures Exclusive Rights to Baiyiyuan Biotech’s Implant in Greater China
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with Shanghai-based...
Shanghai Pharmaceuticals Halts Development of B001 and I022 for Selected Indications
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced the discontinuation of clinical studies and...
Shanghai Turtle Technology Partners with Focusgen Biotech to Advance Tumor Liquid Biopsy Innovations
Shanghai Turtle Technology Co., Ltd, a leading Polymerase Chain Reaction (PCR) specialist in China, has...
Brii Biosciences’ BRII-179 Shows Promise in Phase II Trials for Chronic Hepatitis B at EASL 2024
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has presented new...
AI-Powered Biotech Insilico Medicine Initiates Phase I Clinical Trial for Inflammatory Bowel Disease Drug
Insilico Medicine, a China-based biotechnology company at the forefront of generative artificial intelligence (AI), has...
China’s NMPA Issues New Supervision Measures for Medical Device Clinical Trials Starting October 2024
The National Medical Products Administration (NMPA) has approved the “Measures for Supervision and Inspection of...
Jiangxi Fushine’s Subsidiary LinkChem Eyes Hong Kong IPO Amid Strong Revenue Growth
Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE: 300497), a Chinese pharmaceutical company, has announced that its...
Merck Boosts Global Distribution Capabilities with €180 Million Expansion of German Center
Merck KGaA (ETR: MRK), the German life science and technology company, announced last week a...
Gilead’s Bulevirtide-PegIFN Combo Achieves High HDV Remission Rates in Phase IIb Trial
Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company at the forefront of HIV and liver...
AbbVie’s Telisotuzumab Vedotin Earns Breakthrough Therapy Designation in China for c-Met Positive NSCLC
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced that...
MSD Makes Undisclosed Equity Investment in Cancer Diagnostics Firm DELFI Diagnostics
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an equity investment into DELFI Diagnostics,...
GSK Finalizes Acquisition of Oligonucleotide Specialist Elsie Biotechnologies for Up to $50 Million
GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has announced the completion of the...
Four More Chinese Provinces Include ART in Medical Insurance Payment System
The provincial governments of Jiangxi, Shanghai, Qinghai, and Zhejiang have added assisted reproductive technology (ART)...
J&J Loses US Court Case Over Asbestos in Cosmetic Products; Ordered to Pay $260 Million
Johnson & Johnson (J&J; NYSE: JNJ) suffered a defeat in a US court this week,...
MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as...